The DOI matches its Crossref record; 31 of the 31 references it cites were found in a registry or an index.
Serum Paraoxonase After Myocardial Infarction
Abstract
Abstract —HDL has been shown to prevent the oxidative modification of LDL. The antioxidant activity of HDL is believed to reside in its enzymes, particularly paraoxonase. Human serum paraoxonase (PON1) is closely associated with a specific HDL subfraction also containing apoA1 and clusterin. Recently PON1 has been implicated in the pathogenesis of atherosclerosis. We have examined the activity, concentration, and specific activity of PON1 in 50 patients on admission to hospital immediately after acute myocardial infarction (MI) and in 48 age- and gender-matched controls. Serum PON1 activity and concentration were significantly lower in patients with MI than in controls (activity, 221.5 [99.3 to 303.2] nmol · min −1 · mL −1 in controls and 130.1 [78.9 to 230.3] nmol · min −1 · mL −1 in MI patients [ P <0.05]; concentration, 95.7 [73.2 to 135.5] μg/mL in controls and 35.4 [21.6 to 51.3] μg/mL in MI patients [ P <0.001]). PON1-specific activity was significantly higher in patients with MI than in controls (1.5 [0.9 to 2.9] versus 3.4 [2.0 to 8.5] nmol · min −1 · μg −1 [ P <0.001]) due to the much lower PON1 concentration. PON1 activity had risen significantly ( P <0.05) to 158.1 (85.4 to 282.0) nmol · min −1 · mL −1 at day 42 but was still significantly less than that of controls. No significant variation in PON1 concentration occured in the days after MI or at 6 weeks. Also, no significant variation in specific activity was seen after MI. When the patients were divided into subgroups based on whether or not they received thrombolytic therapy on admission to hospital, no significant difference in PON1 levels was observed. Serum HDL cholesterol in patients with MI on admission was not significantly different than in controls, and the decrease that occurred by the fifth day after MI did not explain the lower PON1 levels. We conclude that low serum PON1 activity in patients with MI may be a consequence of the coronary event itself or could have been present before MI. The low PON1 activity was also not explicable on the basis of PON1 genotypes because the prevalence of genotypes associated with low activity was not sufficient to explain fully the difference in activity levels between patients and controls. The explanation for the low PON1 activity was most likely a decrease in serum PON1 concentration. The importance of PON1 as a predictive risk factor for MI should be assessed in future studies.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Epstein, F. H., Steinberg, D., Parthasarathy, S., Carew, T. E., Khoo, J. C., & Witztum, J. L. (1989) · New England Journal of Medicine · doi:10.1056/nejm198904063201407 · Cited by 6,427
Autoantibody against oxidised LDL and progression of carotid atherosclerosis
Salonen, J. T., Korpela, H., Salonen, R., Nyyssonen, K., Yla-Herttuala, S., Yamamoto, R., Butler, S., Palinski, W., & Witztum, J. L. (1992) · The Lancet · doi:10.1016/0140-6736(92)90926-t · Cited by 1,316
Watson, A. D., Berliner, J. A., Hama, S. Y., La Du, B. N., Faull, K. F., Fogelman, A. M., & Navab, M. (1995) · Journal of Clinical Investigation · doi:10.1172/jci118359 · Cited by 1,154
Paraoxonase prevents accumulation of lipoperoxides in low‐density lipoprotein
Mackness, M. I., Arrol, S., & Durrington, P. N. (1991) · FEBS Letters · doi:10.1016/0014-5793(91)80962-3 · Cited by 977
Self-citationThe molecular basis of the human serum paraoxonase activity polymorphism
Humbert, R., Adler, D. A., Disteche, C. M., Hassett, C., Omiecinski, C. J., & Furlong, C. E. (1993) · Nature Genetics · doi:10.1038/ng0193-73 · Cited by 841
Van Lenten, B. J., Hama, S. Y., de Beer, F. C., Stafforini, D. M., McIntyre, T. M., Prescott, S. M., La Du, B. N., Fogelman, A. M., & Navab, M. (1995) · Journal of Clinical Investigation · doi:10.1172/jci118345 · Cited by 840
High-density lipoprotein inhibits the oxidative modification of low-density lipoprotein
Parthasarathy, S., Barnett, J., & Fong, L. G. (1990) · Biochimica et Biophysica Acta (BBA) - Lipids and Lipid Metabolism · doi:10.1016/0005-2760(90)90314-n · Cited by 827
MACKNESS, M., ARROL, S., ABBOTT, C., & DURRINGTON, P. (1993) · Atherosclerosis · doi:10.1016/0021-9150(93)90183-u · Cited by 816
Self-citationAldridge, W. N. (1953) · Biochemical Journal · doi:10.1042/bj0530110 · Cited by 741
Navab, M., Imes, S. S., Hama, S. Y., Hough, G. P., Ross, L. A., Bork, R. W., Valente, A. J., Berliner, J. A., Drinkwater, D. C., & Laks, H. (1991) · Journal of Clinical Investigation · doi:10.1172/jci115532 · Cited by 737
The effect of the human serum paraoxonase polymorphism is reversed with diazoxon, soman and sarin
Davies, H. G., Richter, R. J., Keifer, M., Broomfield, C. A., Sowalla, J., & Furlong, C. E. (1996) · Nature Genetics · doi:10.1038/ng1196-334 · Cited by 603
Susceptibility to low-density lipoprotein oxidation and coronary atherosclerosis in man
Regnstrom, J., Nilsson, J., Tornvall, P., Hamsten, A., & Landou, C. (1992) · The Lancet · doi:10.1016/0140-6736(92)91129-v · Cited by 574
Serum paraoxonase activity in familial hypercholesterolaemia and insulin-dependent diabetes mellitus
Mackness, M. I., Harty, D., Bhatnagar, D., Winocour, P. H., Arrol, S., Ishola, M., & Durrington, P. N. (1991) · Atherosclerosis · doi:10.1016/0021-9150(91)90215-o · Cited by 492
Self-citationAdkins, S., Gan, K., Mody, M., & Du, B. N. L. (1993) · PubMed · Cited by 478
Garin, M. C., James, R. W., Dussoix, P., Blanché, H., Passa, P., Froguel, P., & Ruiz, J. (1997) · Journal of Clinical Investigation · doi:10.1172/jci119134 · Cited by 476
Paraoxonase: biochemistry, genetics and relationship to plasma lipoproteins
Mackness, M. I., Mackness, B., Durrington, P. N., Connelly, P. W., & Hegele, R. A. (1996) · Current Opinion in Lipidology · doi:10.1097/00041433-199604000-00004 · Cited by 447
Self-citationAldridge, W. N. (1953) · Biochemical Journal · doi:10.1042/bj0530117 · Cited by 446
HDL, its enzymes and its potential to influence lipid peroxidation
Mackness, M. I., & Durrington, P. N. (1995) · Atherosclerosis · doi:10.1016/0021-9150(94)05524-m · Cited by 418
Self-citationAbbott, C. A., Mackness, M. I., Kumar, S., Boulton, A. J., & Durrington, P. N. (1995) · Arteriosclerosis, Thrombosis, and Vascular Biology · doi:10.1161/01.atv.15.11.1812 · Cited by 387
Self-citationGln-Arg192 polymorphism of paraoxonase and coronary heart disease in type 2 diabetes
Ruiz, J., Morabia, A., Blanche, H., James, R. W., Garin, M.-C. B., Charpentier, G., Passa, P., Vaisse, C., Ruiz, J., & Froguel, P. (1995) · The Lancet · doi:10.1016/s0140-6736(95)92709-3 · Cited by 344
Serrato, M., & Marian, A. J. (1995) · Journal of Clinical Investigation · doi:10.1172/jci118373 · Cited by 339
Mildly oxidized LDL induces an increased apolipoprotein J/paraoxonase ratio.
Navab, M., Hama-Levy, S., Van Lenten, B. J., Fonarow, G. C., Cardinez, C. J., Castellani, L. W., Brennan, M. L., Lusis, A. J., Fogelman, A. M., & La Du, B. N. (1997) · Journal of Clinical Investigation · doi:10.1172/jci119369 · Cited by 309
Mackness, M. I., Abbott, C., Arrol, S., & Durrington, P. N. (1993) · Biochemical Journal · doi:10.1042/bj2940829 · Cited by 305
Self-citationPharmacogenetics of drug metabolism
Kalow, W. (1980) · Trends in Pharmacological Sciences · doi:10.1016/0165-6147(80)90063-2 · Cited by 289
Shih, D. M., Gu, L., Hama, S., Xia, Y. R., Navab, M., Fogelman, A. M., & Lusis, A. J. (1996) · Journal of Clinical Investigation · doi:10.1172/jci118589 · Cited by 247
Distribution of paraoxon hydrolytic activity in the serum of patients after myocardial infarction.
McElveen, J. E., Mackness, M., COLLEY, C. M., Peard, T., Warner, S., & Walker, C. H. (1986) · Clinical Chemistry · doi:10.1093/clinchem/32.4.671 · Cited by 227
Self-citationMackness, B., Mackness, M. I., Arrol, S., Turkie, W., & Durrington, P. N. (1997) · British Journal of Pharmacology · doi:10.1038/sj.bjp.0701390 · Cited by 211
Self-citationMackness, M., Arrol, S., Mackness, B., & Durrington, P. N. (1997) · The Lancet · doi:10.1016/s0140-6736(05)61755-2 · Cited by 173
Self-citationMackness, M. (1989) · Biochemical Pharmacology · doi:10.1016/0006-2952(89)90376-6 · Cited by 79
Self-citationThe polymorphic paraoxonase/arylesterase isozymes of human serum.
Bn, L. D., & Eckerson, H. W. (1984) · PubMed · Cited by 75
[Antioxidant effect of high-density lipoproteins in the peroxidation of low-density lipoproteins].
Klimov, A. N., Kozhemiakin, L. A., Vm, P., & Andreeva, L. I. (1987) · PubMed · Cited by 26
Cited by
Paraoxonase and Atherosclerosis
Durrington, P. N., Mackness, B., & Mackness, M. I. (2001) · Arteriosclerosis, Thrombosis, and Vascular Biology · doi:10.1161/01.atv.21.4.473 · Cited by 818
Self-citationNavab, M., Hama, S. Y., Anantharamaiah, G. M., Hassan, K., Hough, G. P., Watson, A. D., Reddy, S. T., Sevanian, A., Fonarow, G. C., & Fogelman, A. M. (2000) · Journal of Lipid Research · doi:10.1016/s0022-2275(20)33462-3 · Cited by 668
Aviram, M., Hardak, E., Vaya, J., Mahmood, S., Milo, S., Hoffman, A., Billicke, S., Draganov, D., & Rosenblat, M. (2000) · Circulation · doi:10.1161/01.cir.101.21.2510 · Cited by 460
HDL and the Inflammatory Response Induced by LDL-Derived Oxidized Phospholipids
Navab, M., Berliner, J. A., Subbanagounder, G., Hama, S., Lusis, A. J., Castellani, L. W., Reddy, S., Shih, D., Shi, W., Watson, A. D., et al. (2001) · Arteriosclerosis, Thrombosis, and Vascular Biology · doi:10.1161/01.atv.21.4.481 · Cited by 442
Mackness, B., Davies, G. K., Turkie, W., Lee, E., Roberts, D. H., Hill, E., Roberts, C., Durrington, P. N., & Mackness, M. I. (2001) · Arteriosclerosis, Thrombosis, and Vascular Biology · doi:10.1161/hq0901.094247 · Cited by 435
Self-citation
Metadata
- Authors
- Ayub, A., Mackness, M. I., Arrol, S., Mackness, B., Patel, J., & Durrington, P. N.
- Venue
- Arteriosclerosis, Thrombosis, and Vascular Biology
- Published
- 1999-02
- Volume
- 19
- Issue
- 2
- Pages
- 330-335
- ISSN
- 1079-5642 (ISSN-L)
- 1524-4636
- OpenAlex
- W2093022509
- Cited by
- 287
- References
- 31
- FWCI
- 7.83
- Type
- journal article
- Language
- en
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.